HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cryer, P. E. Search for Related Content PubMed PubMed Citation Articles by Cryer, P. E. Social Bookmarking                What's this?

Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes

From the Division of Endocrinology, Metabolism and Lipid Research and the General Clinical Research Center and Diabetes Research and Training Center, Washington University School of Medicine, St. Louis, Missouri

Iatrogenic hypoglycemia is a problem for people with diabetes. It causes recurrent morbidity, and sometimes death, as well as a vicious cycle of recurrent hypoglycemia, precluding maintenance of euglycemia over a lifetime of diabetes. Improved therapeutic approaches that will minimize both hypo- and hyperglycemia will be based on insight into the pathophysiology of glucoregulation, specifically glucose counterregulation, in insulin-deficient (type 1 and advanced type 2) diabetes. In such patients, hypoglycemia is the result of the interplay of relative or absolute therapeutic insulin excess and compromised physiological (the syndrome of defective glucose counterregulation) and behavioral (the syndrome of hypoglycemia unawareness) defenses against falling plasma glucose concentrations. The concept of hypoglycemia-associated autonomic failure (HAAF) in diabetes posits that recent antecedent iatrogenic hypoglycemia causes both defective glucose counterregulation (by reducing epinephrine responses to a given level of subsequent hypoglycemia in the setting of absent decrements in insulin and absent increments in glucagon) and hypoglycemia unawareness (by reducing sympathoadrenal and the resulting neurogenic symptom responses to a given level of subsequent hypoglycemia) and thus a vicious cycle of recurrent hypoglycemia. The clinical impact of HAAF is well established in type 1 diabetes; it also affects those with advanced type 2 diabetes. It is now known to be largely reversible, by as little as 2–3 weeks of scrupulous avoidance of hypoglycemia, in most affected patients. However, the mechanisms of HAAF and its component syndromes are largely unknown. Loss of the glucagon secretory response, a key feature of defective glucose counterregulation, is plausibly explained by insulin deficiency, specifically loss of the decrement in intraislet insulin that normally signals glucagon secretion as glucose levels fall. Reduced neurogenic symptoms, a key feature of hypoglycemia unawareness, are largely the result of reduced sympathetic neural responses to falling glucose levels. The mechanism by which hypoglycemia shifts the glycemic thresholds for sympathoadrenal activation to lower plasma glucose concentrations, the key feature of both components of HAAF, is not known. It does not appear to be the result of the release of a systemic mediator (e.g., cortisol, epinephrine) during antecedent hypoglycemia or of increased blood-to-brain glucose transport (although increased transport of alternative fuels is conceivable). It is likely the result of alterations of brain metabolism. Although there is an array of clues, the specific alteration remains to be identified. While the research focus has been largely on the hypothalamus, hypoglycemia is now known to activate widespread brain regions, including the medial prefrontal cortex. The possibility that HAAF could be the result of posthypoglycemic brain glycogen supercompensation has also been raised. Finally, there appear to be diverse causes of HAAF. In addition to recent antecedent hypoglycemia, these include exercise- and sleep-related HAAF. Clearly, a unifying mechanism of HAAF would need to incorporate these causes as well. Pending the prevention and cure of diabetes, critical fundamental, translational, and outcomes research is needed if we are to eliminate hypoglycemia from the lives of people affected by diabetes.

Abbreviations: CNS, central nervous system; HAAF, hypoglycemia-associated autonomic failure; K_ATP channel, ATP-sensitive K⁺ channel; PET, positron emission tomography; VMH, ventromedial hypothalamus

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. M. Arbelaez, W. J. Powers, T. O. Videen, J. L. Price, and P. E. Cryer Attenuation of Counterregulatory Responses to Recurrent Hypoglycemia by Active Thalamic Inhibition: A Mechanism for Hypoglycemia-Associated Autonomic Failure Diabetes, February 1, 2008; 57(2): 470 - 475. [Abstract] [Full Text] [PDF]

				M. Garcia-Fernandez, P. Ortega-Saenz, A. Castellano, and J. Lopez-Barneo Mechanisms of Low-Glucose Sensitivity in Carotid Body Glomus Cells Diabetes, December 1, 2007; 56(12): 2893 - 2900. [Abstract] [Full Text] [PDF]

				A. V. Matveyenko, M. Bohland, M. Saberi, and C. M. Donovan Portal vein hypoglycemia is essential for full induction of hypoglycemia-associated autonomic failure with slow-onset hypoglycemia Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E857 - E864. [Abstract] [Full Text] [PDF]

				S. Fujita, M. Bohland, G. Sanchez-Watts, A. G. Watts, and C. M. Donovan Hypoglycemic detection at the portal vein is mediated by capsaicin-sensitive primary sensory neurons Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E96 - E101. [Abstract] [Full Text] [PDF]

				M. R. Rickels, M. H. Schutta, R. Mueller, S. Kapoor, J. F. Markmann, A. Naji, and K. L. Teff Glycemic Thresholds for Activation of Counterregulatory Hormone and Symptom Responses in Islet Transplant Recipients J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 873 - 879. [Abstract] [Full Text] [PDF]

				T. Alquier, J. Kawashima, Y. Tsuji, and B. B. Kahn Role of Hypothalamic Adenosine 5'-Monophosphate-Activated Protein Kinase in the Impaired Counterregulatory Response Induced by Repetitive Neuroglucopenia Endocrinology, March 1, 2007; 148(3): 1367 - 1375. [Abstract] [Full Text] [PDF]

				Z. Song and V. H. Routh Recurrent hypoglycemia reduces the glucose sensitivity of glucose-inhibited neurons in the ventromedial hypothalamus nucleus Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1283 - R1287. [Abstract] [Full Text] [PDF]

				N. C. Tkacs and H. J. Thompson From bedside to bench and back again: research issues in animal models of human disease. Biol Res Nurs, July 1, 2006; 8(1): 78 - 88. [Abstract] [PDF]

				V. J. Briscoe and S. N. Davis Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management Clin. Diabetes, July 1, 2006; 24(3): 115 - 121. [Abstract] [Full Text] [PDF]